418
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden

, , , &
Pages 504-514 | Received 09 Sep 2010, Accepted 17 Jan 2011, Published online: 18 Feb 2011

References

  • Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993;167:1247–51.
  • Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133–63.
  • Mahfouz T, Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 2003; 4:974–90.
  • Peres-Bota D, Rodriguez-Villalobos H, Dimopoulos G, Melot C, Vincent JL. Potential risk factors for infection with Candida spp. in critically ill patients. Clin Microbiol Infect 2004;10:550–5.
  • Maartens G, Wood MJ. The clinical presentation and diagnosis of invasive fungal infections. J Antimicrob Chemother 1991;28:13–22.
  • Bodey GP, Knotoyiannis DP, Lewis RE. Empiric antifungal therapy for persistently febrile neutropenic patients. Curr Treat Opt Infect Dis 2002;4:521–32.
  • Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, . 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730–51.
  • Torfs K. Economic aspects of treatment for fungal infections in cancer patients. Eur J Clin Microbiol Infect Dis 1997; 16:98–107.
  • Erjavec Z, Kluin-Nelemans H, Verweij PE. Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Eur Soc Clin Microbiol Infect Dis 2009;15:625–33.
  • Klingspor L, Törnqvist E, Johansson A, Petrini B, Forsum U, Hedin G. A prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 2004;36:52–5.
  • Böhme A, Ruhnke M, Buchheidt D, Karthaus M, Cornely O, Einsele H, . Treatment of invasive fungal infections in cancer patients—recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009;88:97–110.
  • Jorgensen JJ, Gotzsche PC, Johansen KH. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2006;1:CD004704.
  • Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, . A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155–63.
  • Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, . Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351: 1391–402.
  • Prentice AG, Glasmacher A, Hobson RP, Schey S, Barnes RA, Donnelly JP, . Guidelines on the management of invasive fungal infection during therapy for haematological malignancy. London: British Committee for Standards in Haematology; 2010.
  • Bruynesteyn K, Gant V, McKenzie C, Pagliuca T, Poynton C, Kumar RN, Jansen JP. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol 2007; 78:532–9.
  • Kaskel P, Tuschy S, Wagner A, Bannert C, Cornely O, Glasmacher A, . Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Ann Hematol 2008;87:311–9.
  • Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, . Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 34:225–34.
  • Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, . Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764–71.
  • Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, . Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39:1563–71.
  • Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, . Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113: 4179–87.
  • Swedish Lymphoma Registry. Svenska Lymfomregistret Rapport förår 2000–2006. Available from URL: http://www.ocsyd.se/VP-verksamhet/Kvalitetsreg/Svenskalymfom registretRapport2000–2006.pdf (accessed date: December 2009).
  • Centre for Epidemiology, National Board of Health and Welfare. Cancer patient survival in Sweden 1980–2002. Sweden: National Board of Health and Welfare; 2004. Available at: http://www.socialstyrelsen.se/english/statisticaldatabases/Sidor/cancersurvival-predictions2004.aspx (accessed date: December 2009).
  • Apoteket AB. Apoteket p tv minuter. 2009. Available from URL: http://www.apoteket.se/privatpersoner/common/search.aspx?q=caspofungin
  • Prislista Akademiska sjukhuset i Uppsala (Uppsala University Hospital price list). Available from URL: http://www.externt9.lul.se/svn/akademiska09.xls (accessed date: December 2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.